Amgen

Open: 282.09 Close: 280.6 Change: -1.49

You're running out of time to find out about Amgen Company Inc Stock using an AI.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, call, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen closed at $283.58 in the latest trading session, marking a.3% move from the prior day. Amgen has an ESP ESP+ of +165%.

Today's News

Amgen is excited to showcase data that demonstrate the progress we are making across a range of tough to treat cancers, including small cell lung cancer, metastatic colorectal cancer (mCRC) and prostate cancer. Amgens most recent quarter was expected to post $5 per share, but it reported $5 instead of a surprise, representing a 12-point increase. Amgen has an ESP ESP+ of +165% at the moment. Amgen (AMGN) stock moves -0.3%: what you should know - October 18, 2023 - Zacks.com. Amgen closed at $283.58 in the latest trading session, marking a.3% move from the prior day. Market participants will be closely following the financial results. Amgen to webcast investor call at esmo 2023. amgen to Webcast investor conference at 8:00 a.m. October 24. Amgen Inc. (amgn) latest stock news. Follow us on Twitter @Amgen inc. (AMGN) Latest Stock News. Amgen on linkedin: Happy Holidays from Amgen! U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the history. see which of the latest 13f filers holds amgen. Amgen announces financial results for the second quarter of 2023. Positive Top-Line Results for Tarlatamab in Small Cell Lung Cancer. Amgen to webcast investor call at esmo 2023. Amgen will host a webcasted call for the investment community at 8:00 a.m. on October 24, 2023. The webcast will follow presentation of new data from Amgens innovative oncology portfolio. Amgen to webcast investor call at esmo 2023. Investors who purchased Amgen securities prior to July 29, 2020, and continue to hold to the present, are encouraged to obtain additional information. Amgen to webcast investor call at esmo 2023. Amgen will present new data from Amgens innovative oncology portfolio at 8:00 a.m. on October 24, 2023 following presentation of new data. Abbott stock (NYSE: ABT) is a better healthcare pick than Amgen stock (NASDAQ NDAQ : AMGN) Given its better prospects, we believe Abbotts revenue growth has been better. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Tarlatamab is an investigational, targeted immunotherapy engineered by Amgen researchers. Amgen to webcast investor call at esmo 2023. Amgen will host a webcasted call for the investment community at 8:00 a.m. on October 24, 2023 following presentation of new data. Amgen to webcast investor call at esmo 2023. Amgen will host a webcasted call for the investment community at 8:00 a.m. on October 24, 2023. Amgen is an Equal Opportunity Employer.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, call, webcast, investor, October, esmo, data, and the most common words in the summary are: amgen, stock, news, job, market, inc, best, . One of the sentences in the summary was: Amgen has an ESP ESP+ of +165%.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #news #job #market #inc #best.